Company intelligence / Profile preview

SPH Kyuan (Shanghai) Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Employees: ~30
Development stage: Other

Overview

SPH Kyuan is (or was) a Shanghai Pharmaceuticals subsidiary focused on import, bonded warehousing, and nationwide distribution of drugs, vaccines, and medical devices in China, acting as a commercial partner for products such as eravacycline and trientine tetrahydrochloride rather than developing its own pipeline.[2][3][5][6][7]

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Everest Medicines (commercialization and distribution of eravacycline (XERAVA) for complicated intra-abdominal infections in China)[2][5][9]Orphalan (commercialization and distribution partnership for trientine tetrahydrochloride for Wilson disease in China via SPH Kyuan Trade)[6][7]

Beyond the preview

Go deeper on SPH Kyuan (Shanghai) Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH Kyuan (Shanghai) Pharmaceutical.

Explore the full profile